Remogliflozin etabonate
Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by , a wholly owned subsidiary of North Carolina USA-based , and Glenmark Pharmaceuticals through a collaboration with BHV. Remogliflozin was commercially launched first in India by Glenmark in May 2019.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Remogliflozin etabonate
Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by , a wholly owned subsidiary of North Carolina USA-based , and Glenmark Pharmaceuticals through a collaboration with BHV. Remogliflozin was commercially launched first in India by Glenmark in May 2019.
has abstract
Remogliflozin etabonate (INN/U ...... India by Glenmark in May 2019.
@en
CAS number
442201-24-3
ChEMBL
FDA UNII code
TR0QT6QSUL
KEGG
Wikipage page ID
18,775,455
page length (characters) of wiki page
Wikipage revision ID
979,866,175
Link from a Wikipage to another Wikipage
ATC prefix
none
@en
CAS number
ChEMBL
ChemSpiderID
IUPAC name
KEGG
D10055
@en
legal status
Investigational
@en
routes of administration
SMILES
OC1COCOcc2Cc3cccOCC
@en
StdInChIKey
UAOCLDQAQNNEAX-ABMICEGHSA-N
@en
UNII
TR0QT6QSUL
@en
Verifiedfields
changed
@en
verifiedrevid
401,621,521
wikiPageUsesTemplate
hypernym
comment
Remogliflozin etabonate (INN/U ...... India by Glenmark in May 2019.
@en
label
Remogliflozin etabonate
@en